Reply to: "The "cholesterol paradox" in patients with mastocytosis"

Ilze Bot; Monique T Mulder; Swasti Indhirajanti; Paul L A van Daele; Jeanine E Roeters van Lennep

doi:10.1016/j.atherosclerosis.2019.02.018

Reply to: "The "cholesterol paradox" in patients with mastocytosis"

Atherosclerosis. 2019 May:284:262-263. doi: 10.1016/j.atherosclerosis.2019.02.018. Epub 2019 Mar 2.

Authors

Ilze Bot¹, Monique T Mulder², Swasti Indhirajanti³, Paul L A van Daele⁴, Jeanine E Roeters van Lennep⁵

Affiliations

¹ Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
² Department of Internal Medicine, Laboratory Vascular Medicine, Erasmus MC, Rotterdam, the Netherlands.
³ Department of Internal Medicine, Franciscus Gasthuis & Vlietland, the Netherlands.
⁴ Department of Internal Medicine, Division Immunology, and Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.
⁵ Department of Internal Medicine, Laboratory Vascular Medicine, Erasmus MC, Rotterdam, the Netherlands. Electronic address: j.roetersvanlennep@erasmusmc.nl.

PMID: 30871724
DOI: 10.1016/j.atherosclerosis.2019.02.018

No abstract available

Keywords: Atherosclerosis; Cardiovascular risk; Cholesterol; High-density lipoprotein; Lipoproteins; Low-density lipoprotein; Mast cells; Risk factors; Systemic mastocytosis.

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases*
Cholesterol
Humans
Lipoproteins, LDL
Mastocytosis*
Mastocytosis, Systemic*

Substances

Lipoproteins, LDL
Cholesterol